The German transregional collaborative research centre inflammatory cardiomyopathy - Molecular pathogenesis and therapy

Cardiology

Volumn 113, Issue 3, 2009, Pages 222-230

  Angelow, A ^a   Weitmann, K ^a   Schmidt, M ^a   Schwedler, S ^a   Vogt, H ^a   Havemann, C ^a   Staudt, A ^b   Felix, S B ^b   Stangl, K ^d   Klingel, K ^c   Kandolf, R ^c   Kuhl U ^d   Lassner, D ^e   V Schlippenbach, J ^d   Schultheiss, H P ^d   Hoffmann, W ^a,f  

^a Institut für Community Medicine   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Institut Kardiale Diagnostik und Therapie GmbH   (Germany)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Dilated cardiomyopathy; Inflammatory cardiomyopathy; Myocarditis; Research registry

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CARDIOPULMONARY FUNCTION; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GERMANY; HEALTH BEHAVIOR; HEART DISEASE; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE BIOPSY; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; INFLAMMATORY CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MOLECULAR MECHANICS; MYOCARDITIS; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REGISTER; SOCIAL ASPECT; TREATMENT OUTCOME;

EID: 60749120593     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203404     Document Type: Article

References (37)

1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, and Council on Epidemiology and Prevention. Circulation 2006;113:1807-1816.
2. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al: Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276.
3. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al: A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326-1333.
4. Kallwellis-Opara A, Dorner A, Poller WC, Noutsias M, Kuhl U, Schultheiss HP, et al: Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol 2007;96:469-480.
5. Pankuweit S, Ruppert V, Maisch B: Inflammation in dilated cardiomyopathy. Herz 2004;29:788-793.
6. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R: Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 2004;193:101-107.
7. D'Ambrosio A, Patti G, Manzoli A, Sinagra G, Di LA, Silvestri F, et al: The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001;85:499-504.
8. Liu PP, Mason JW: Advances in the understanding of myocarditis. Circulation 2001;104:1076-1082.
9. Ku hl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al: High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 'idiopathic' left ventricular dysfunction. Circulation 2005;111:887-893.
10. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al: Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-1970.
11. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al: The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circu lation 2007;116:2216-2233.
12. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al: Report of the 1995World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93:841-842.
13. Maisch B, Hufnagel G, Kolsch S, Funck R, Richter A, Rupp H, et al: Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz 2004;29:624-636.
14. Fr ustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Ma ser i A: Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-863.
15. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al: Interferon-beta treatment eliminates cardiotro-pic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-2798.
16. Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, et al: Immuno-adsorption in dilated cardiomyopathy:6-month results from a randomized study. Am Heart J 2006;152:712-716.
17. Knebel F, Böhm M, Staudt A, Borges AC, Tepper M, Jochmann N, et al: Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Ca rdiol 2004;97:517-520.
18. Felix SB, Staudt A, Baumann G: Immunoad-sorption as a new therapeutic principle for treatment of dilated cardiomyopathy. Eur Heart J Suppl 2002;4:I63-I68.
19. Wojn icz R, Nowa la ny-Kozielsk a E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al: Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001;104:39-45.
20. Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, et al: Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000;35:1590-1598.
21. Staudt A, Schäper F, Stangl V, Plagemann A, Böhm M, Merkel K, et al: Immunohistologi-cal changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001;103:2681-2686.
22. Kuhl U, Schultheiss HP: Treatment of chronic myocarditis with corticosteroids. Eur Heart J 1995;16(suppl O):168-172.
23. John U, Greiner B, Hensel E, Lüdemann J, Piek M, Sauer S, et al: Study of health in Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Präventivmed 2001;46:186-194.
24. Rose GA, Blackbur H: Cardiovascular Survey Methods. Geneva, World Health Organization, 1968.
25. Bullinger M: German translation and psychometric testing of the SF-36health survey: preliminary results from the IQOLA Project. Soc Sci Med 1995;41:1359-1366.
26. Rector TS, Cohn JN: Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017-1025.
27. Kuhl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, et al: Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008;80:1243-1251.
28. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ana l Biochem 1987;162:156-159.
29. Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Bio-techniques 1993;15:532-537.
30. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, Pham V, Kuhl U, Schwimmbeck PL, et al: Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999;99:1348-1354.
31. Klingel K, Stephan S, Sauter M, Zell R, Mc-Manus BM, Bultmann B, et al: Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol 1996;70:8888-8895.
32. Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, et al: Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 2003;34:92-95.
33. Noutsias M, Pauschinger M, Schultheiss H, Kühl U: Phenotypic characterization of infiltrates in dilated cardiomyopathy-diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit 2002;8:CR478-CR487.
34. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, et al: Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-648.
35. Mahrholdt H, Wagner A, Deluigi CC, K ispert E, Hager S, Meinhardt G, et al: Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581-1590.
36. Hufnagel G, Pankuweit S, Richter A, Schö-nian U, Maisch B: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epi-demiological results. Herz 2000;25:279-285.
37. Maisch B, Hufnagel G, Schonian U, Heng-stenberg C: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995;16(suppl O):173-175.